357 results about "Pancreatic islets" patented technology

The invention provides a bifidobacterium animalis subsp. Lactis strain B21247 with a hypoglycemic function and application thereof, and belongs to the technical field of functional microorganisms. The invention relates to a bifidobacterium animalis subsp. Lactis strain B21247 with a hypoglycemic function. The preservation number of the bifidobacterium animalis subsp. Lactis strain B21247 is GDMCC No: 65075. The strain B21247 has a good intestinal colonization function, and has the activity of inhibiting alpha-glucosidase in vitro. Meanwhile, a type 2 diabetes mouse model is used as an experimental model to verify that the strain B21247 achieves the effect of reducing blood sugar by adjusting glycosylated hemoglobin, reducing pancreatic beta cell damage and increasing secretion of intestinal GLP-1, and a new thought is provided for reducing blood sugar or treating diabetes.

The invention provides a stem cell exosome vesicle induced by traditional Chinese medicine functional components as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the preparation method of the stem cell exosome vesicle, traditional Chinese medicine functional components serve as an exosome inducer, stem cells can be induced to proliferate and secrete exosome with the enhanced function, the yield of the exosome can be increased, bioactive molecules can be loaded, and the bioavailability of the exosome in diabetes treatment is remarkably improved. The stem cell exosome vesicle disclosed by the invention can be applied to treatment of diabetes and complications thereof, not only can improve functions of islet cells, but also can treat chronic inflammation, microangiopathy and other metabolic diseases related to diabetes, and has a wide clinical application prospect.

Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. Described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic β-cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D β-cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.

The invention belongs to the technical field of organoid culture, and particularly relates to a co-differentiated vascularized islet organoid and a construction method thereof. Aiming at the problems that the existing pancreatic islet organ vascularization mostly adopts a co-culture mode, the operation process is long, the difficulty is high, the randomness is realized, the uniformity is poor and the like, the invention provides the construction method of the co-differentiated vascularized pancreatic islet organ. The method comprises the following steps of: sequentially inducing and culturing directional endoderm cells, original intestinal canal cells and posterior preintestinal cells, and adding a culture medium containing VEGF (vascular endothelial growth factor), BMP4 (bone morphogenetic protein 4) and FGF2 (fibroblast growth factor 2) for culturing in subsequent induced differentiation, so as to obtain the co-differentiated vascularized islet organ. Under the condition that exogenous endothelial cells are not added, the iPS cells are directionally differentiated to generate the vascularized islet organ containing beta, alpha and delta cells and vascular endothelial cells for the first time, the vascularized islet organ is more mature than non-vascularized islet organs and has a stronger insulin secretion function, and a new thought and an experimental basis are provided for realizing functional healing of diabetes mellitus.

The invention relates to a lactic acid bacterium capable of reducing fat, resisting inflammation and reducing blood sugar, which is classified and named as pediococcus acidilactici XJ335, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30093, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain can achieve the fat reducing effect by adjusting the abundance of intestinal flora; the levels of IL-6 and TNF-alpha in serum of diabetic mice are remarkably improved through regulation, so that the anti-inflammatory effect is achieved; various cardiovascular diseases of atherosclerosis are prevented by adjusting the levels of TC, TG, HDL-C and LDL-C; by reducing FINS and HOMA-IR levels and improving HOMA-IS, HOMA-beta and QUICKI value levels, insulin resistance of a body is reduced, insulin sensitivity and pancreas islet beta cell functions of the body are improved, gene expression related to blood sugar regulation is regulated, and an excellent blood sugar reducing effect is achieved in the body.

The invention provides a pancreatic islet organ capable of efficiently maintaining pancreatic islet beta cell identity and a preparation method and application thereof. Specifically, the invention provides the preparation method for the in-vitro pancreatic islet organ, and the preparation method comprises the following steps: carrying out induced differentiation culture on the ZnT8-knocked-out pluripotent stem cells, so as to obtain the mature pancreatic islet organ. The invention also provides a corresponding transplantation composition and application thereof. The invention discloses that ZnT8 knockout is a key factor for effectively maintaining the identity stability of beta cells in pancreatic islet organs. In addition, the pancreas islet beta cell identity maintenance agent is combined with the ZnT8-knocked-out pancreas islet organ for use, so that the identity stability of the pancreas islet organ beta cell can be obviously maintained. The invention provides a new strategy for transplantation treatment of type 2 diabetes, and has excellent clinical transformation value.

The invention relates to the technical field of biological medicines, in particular to application of N-acetyl serotonin in prevention and treatment of diabetes mellitus, and tests show that NAS has an obvious improvement effect on symptoms of weight loss, water intake increase and diet increase of T2DM mice; the NAS is used for improving the fasting blood glucose and the glucose tolerance level of the T2DM mouse; the NAS reduces the glycated serum protein and insulin resistance level of the T2DM mouse; the pancreatic beta cell function and insulin sensitivity of the T2DM mouse are improved. Therefore, the medicine N-acetyl serotonin has a good clinical application prospect in treating the type 2 diabetes mellitus and has important significance in developing a novel medicine composition for treating the type 2 diabetes mellitus.

The invention discloses a composition for assisting in reducing blood sugar and blood fat as well as a preparation method and application thereof, and relates to the technical field of functional compositions. The composition comprises highland barley powder and modified inulin, the preparation method of the highland barley powder comprises the following steps: soaking highland barley grains in a weakly alkaline aqueous solution, and sequentially carrying out first pulse microwave treatment, enzyme deactivation treatment and segmented baking treatment; the segmented baking treatment comprises first-stage baking treatment and second-stage intermittent infrared irradiation treatment; the temperature of the first-stage baking treatment is 40-60 DEG C; the temperature of the second-stage intermittent infrared irradiation treatment is 60-80 DEG C, and the emission wavelength is 2.5-4 microns; the preparation method of the modified inulin comprises the following steps: performing acidolysis treatment on inulin in a weakly acidic aqueous solution, and then drying. The highland barley powder and the modified inulin in the embodiment can synergistically improve glycometabolism and lipid metabolism, effectively reduce the body weight, blood sugar, blood fat and the like under high-glucose and / or high-fat diet, and protect and repair the pancreas islet function.

The present invention belongs to the field of biomedical engineering technology, and specifically relates to a hydrogel microfiber carrying pancreatic islet α and β cells, a preparation method and an application thereof; the preparation method comprises: dissolving a photoinitiator in a cross-linked water-soluble polymer solution, filtering and sterilizing, adding pancreatic islet α and β cells to obtain a hydrogel cell prepolymer solution, passing the hydrogel cell prepolymer solution into an inner phase tube, passing an ionically cross-linked aqueous phase solution into an outer phase tube, and adjusting the flow rates of the solutions in the inner and outer phase tubes so that the liquids form a mutually immiscible laminar flow state; in a microfluidic device, after the inner phase solution contacts the outer phase solution, the ionically cross-linked components in the inner phase solution undergo ionically cross-linking with the outer phase solution to preliminarily form hydrogel microfibers, which are then secondary cross-linked by 405nm blue light irradiation to ultimately form hydrogel microfibers carrying pancreatic islet α and β cells.

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

The invention relates to a heparinized gelatin / sodium alginate pancreas islet packaging material with an anti-fibrosis function as well as a preparation method and application of the heparinized gelatin / sodium alginate pancreas islet packaging material. The preparation method comprises the following steps: adding gelatin into normal saline, soaking, performing autoclaved sterilization to obtain a gelatin solution, then adding epsilon-polylysine hydrochloride into the gelatin solution, and finally adding glutamine transaminase for reaction to obtain an epsilon-polylysine grafted gelatin solution; adding heparin into the solution, and reacting to obtain a heparinized gelatin solution; adding sodium alginate and glutamine transaminase, reacting, diluting, preparing hydrogel microspheres by adopting an electrostatic spraying method, and cross-linking to obtain the hydrogel microspheres. According to the invention, heparin molecules are incorporated into a pancreas islet packaging system, so that fibrosis at the periphery of the microspheres can be relieved, the pancreas islet cells are packaged by using the pancreas islet packaging material to prepare the biological artificial pancreas, the pancreas islet cell proliferation and insulin secretion can be promoted, and the pancreas islet packaging material has a good diabetes treatment effect.

The invention belongs to the technical field of biomedicine, and discloses a structure of linear chaetoceros alkali extraction polysaccharide and an application method in anti-T2DM, methyl GC-MS and NMR are adopted to research the structure of polysaccharide CBS2, and the result shows that CBS2 is mainly composed of [-> 4)-beta-L-Arap-(1->] and contains a small amount of [-> 4)-beta-D-Galp-(1->] and [-> 2)-alpha-L-Rhap-(1->], and the CBS2 has the advantages that the structure of the polysaccharide CBS2 is improved; and a sulfuric acid group is located at a C-3 / C-2 position of [-> 4)-beta-L-Arap-(1->]. The research on the anti-diabetic activity of the polysaccharide CBS2 shows that the CBS2 can inhibit the aggregation of hIAPP, can play a role in protecting pancreatic beta cells by improving the oxidative stress caused by hIAPP and protecting the mitochondrial function, has better anti-diabetic activity, and is a potential compound of anti-diabetic drugs.

The invention provides universally acceptable “off-the-shelf” hypoimmunogenic pluripotent cells and differentiated cardiac, endothelial, neuronal, islet, or retinal pigment cells thereof. Such hypoimmune cells are used to treat patients in need thereof. The cells lack major immune antigens that trigger immune responses and are engineered to avoid phagocytic endocytosis.

The invention relates to the technical field of biological medicines, in particular to a mesenchymal stem cell preparation for treating diabetes and a preparation method thereof. The stem cell preparation is prepared from the following components: umbilical cord mesenchymal stem cells and naringin coated SiO2, and preparation raw materials of the naringin coated SiO2 are prepared from the following components in parts by weight: 10 to 15 parts of tetraethoxysilane (TEOS), 4 to 6 parts of 3-mercaptopropyl oxysilane (MPTMS), 2 to 3 parts of naringin, 0.8 to 1.2 parts of succinic anhydride and 2 to 3 parts of cysteamine hydrochloride. The prepared stem cell preparation has synergistic blood lineage of each component, and can repair pancreas islet injury and inhibit inflammatory response.

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some embodiments, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some embodiments, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

The invention belongs to the technical field of biomedicine, and relates to a method for increasing the yield of pancreas islet organs differentiated by pluripotent stem cells and improving the stability. The method comprises the following steps: (1) inoculating pluripotent stem cells, and culturing by adopting a basic culture medium containing Y-27632; (2) changing the liquid, and continuously culturing by adopting a basic culture medium; (3) culturing for 1 day by using an S1D1 culture medium, and then culturing for 2-3 days by using an S1D2 culture medium; (4) changing the liquid, and culturing for 2-3 days by adopting the S2 culture medium; (5) changing the liquid, and culturing for 1-2 days by adopting an S3 culture medium; (6) changing the liquid, and culturing for 4-7 days by adopting a culture medium S4; (7) changing the liquid, and culturing for 3-10 days by adopting an S5 culture medium; and (8) carrying out cell sphere repolymerization, and culturing for 3-21 days by using an S6 culture medium to obtain the pancreas islet organ. The present invention increases the yield and differentiation efficiency at each differentiation stage and increases the scale yield at the cellular level.

The present disclosure provides methods of producing a population of endodermal stem cells (EnSC), a population of EnSC-derived PP cells, a population of EnSC-derived EP cells, or regenerative pancreatic islet tissue (E-islets). The disclosure also relates to EnSC, EnSC-derived PP cells, EnSC-derived EP cells or regenerated pancreatic islet tissue obtained using the method, and therapeutic uses thereof.

The invention relates to the technical field of biological pharmacy, in particular to application of a recombinant protein DEL-1 in preparation of a medicine for resisting pancreatic beta cell inflammation. The recombinant protein DEL-1 has a remarkable inhibition effect on pancreatic beta cell inflammatory response induced by high glucose and high fat. Experiments show that in an islet beta cell inflammation model constructed by combining high glucose with palmitic acid, DEL-1 can significantly reduce the expression level of inflammatory factors such as IL-1beta, IL-6, TNF-alpha and the like. The DEL-1 is proved to have a definite effect of resisting pancreatic beta cell inflammation.

The invention relates to the technical field of health-care products, in particular to a health-care product rich in momordica charantia polypeptide and capable of regulating blood sugar metabolism and promoting insulin secretion, momordica charantia polypeptide can stimulate pancreatic beta cells to secrete insulin, and insulin is the only hormone capable of reducing blood sugar in a human body. The balsam pear polypeptide component in the balsam pear extract is specially used for reducing the blood sugar level and improving related health problems, the application of the balsam pear polypeptide in the health care product can effectively regulate the blood sugar metabolism of a human body and promote the secretion of insulin, and the balsam pear polypeptide stimulates pancreas islet beta cells to promote the secretion of insulin. In addition, the balsam pear polypeptide can improve the insulin resistance, increase the number of insulin receptors or enhance the activity of the insulin receptors, so that the body cells are more sensitive to the insulin, the uptake and utilization of glucose are promoted, and the abnormal increase of the blood glucose level is avoided.

The invention provides a formula for regulating hyperglycemia by probiotics and a preparation method of the formula, and relates to the technical field of the probiotics, the formula comprises two formulas, the formula I comprises the probiotics, hypoglycemic pepper, raw malt, burdock, snow pear and the like, and the formula II comprises the probiotics, the hypoglycemic pepper, the raw malt, the burdock, the snow pear and the like; and the formula II consists of inonotuso bliquus polysaccharide, schizophyllum commune, chromium yeast, soybean peptide powder and lactobacillus fermentation product powder. The two formulas can be taken independently, alternately or jointly, and are used for regulating the blood sugar level of patients with hyperglycemia or type 2 diabetes mellitus. The probiotic powder contains a plurality of strains with high activity and high viable count, and plays a role in digesting and absorbing basic metabolism. The natural components in the formula have a hypoglycemic effect, and play a role in improving the secretion function of pancreas islet beta cells, improving insulin sensitivity, delaying absorption of carbohydrates, helping produce saliva and slake thirst, diluting blood sugar and other mechanisms.

The present invention relates to a peptide complex having an antidiabetic activity and to a use thereof. The peptide complex of the present invention promotes uptake of glucose into cells, suppresses insulin resistance signals, promotes insulin sensitivity signals, and suppresses the death of pancreatic beta cells, which are insulin-producing cells, thereby exhibiting an effect of lowering blood glucose levels. In addition, the present invention relates to a peptide having an antidiabetic activity and an antiobesity activity and to a use thereof. The peptide of the present invention has an activity of suppressing insulin resistance signals, promoting insulin sensitive signals, and promoting fat decomposition in adipocytes.

The invention relates to a mitochondrial uncoupling inhibitor sustained-release nanodot, a preparation method thereof and application of the nanodot in type 2 diabetes mellitus, and belongs to the technical field of nano-drugs. According to the preparation method disclosed by the invention, glycine and genipin are subjected to Schiff reaction to prepare the slow-release nanodot, and the slow-release nanodot is of a monodisperse spherical structure, has surface negative charges, and can slowly release genipin under physiological conditions, so that the mitochondrial protection effect of the genipin is fully exerted. The mitochondrial uncoupling inhibitor slow-release nanodot prepared by the invention can obviously improve the mitochondrial membrane potential, increase the cell ATP content, effectively inhibit mtDNA release under the stimulation of IL-1beta and palmitic acid, effectively inhibit STING inflammation pathway activation under the stimulation of IL-1beta and PA, obviously reduce pancreatic beta cell apoptosis, obviously relieve endoplasmic reticulum stress, and can be used for preparing the mitochondrial uncoupling inhibitor slow-release nanodot. The T2DM mouse blood sugar is obviously reduced, the glucose tolerance dose and the insulin sensitivity are improved, and good biocompatibility is achieved.

The invention discloses a composite combined preparation for synergistically treating and conditioning diabetes, relates to the technical field of foods, health foods or dietary supplements for adjuvant therapy and health care of diabetes, and in particular relates to a composite combined preparation for synergistically treating and conditioning diabetes. The preparation comprises albumin peptide, saussurea involucrata culture, vitamin B1, vitamin B2, wheat oligopeptide, corn oligopeptide, collagen peptide, mulberry leaf extract, rhizoma polygonati extract, sea-buckthorn extract, isomaltitol, maltodextrin, ginseng extract and bitter gourd extract. Through the synergistic effect of all the components, comprehensive auxiliary conditioning on diabetes is realized from multiple targets of maintaining colloid osmotic pressure and nutrition, regulating glycolipid metabolism in multiple ways, protecting pancreatic beta cell functions, enhancing insulin sensitivity, preventing nerve and blood vessel complications, meeting special diet requirements and the like. The composition can be prepared into food, health-care food or dietary supplement and other dosage forms.

The invention belongs to the technical field of polysaccharide extraction, and particularly relates to mesona chinensis polysaccharide with glycometabolism regulating activity, which is prepared by the steps of micro-fermentation drying, raw material pretreatment, pulping, targeted extraction of polysaccharide, primary separation of polysaccharide, secondary separation of polysaccharide, polysaccharide purification, polysaccharide drying and the like. The mesona chinensis polysaccharide prepared by the method disclosed by the invention has good effects of inhibiting the activity of alpha-glucosidase, improving pancreas beta cell injury and the like, i.e., the mesona chinensis polysaccharide has relatively strong glucosyl metabolism regulating activity.

The invention relates to an islet repair ICK mode oral polypeptide optimization system taking VDAC1 as a target based on ESM2 and a genetic algorithm, and the system comprises a mutation module which is used for carrying out mutation and recombination by adopting the genetic algorithm according to original protein sequence data to generate an initial population; the prediction module is used for respectively inputting the protein sequence data of the initial population into a protein dimer dissociation energy prediction model, a protein toxicity prediction model and a protein cell penetrability prediction model to obtain a dissociation energy prediction value delta G, a toxicity probability value T and a cell membrane passing transmission probability Ed; and the optimization module is used for acquiring the optimal individual performance of the highest fitness score to output the Pareto optimal sequence index, and recording the hotspot residue distribution and the site mutation frequency at the same time. On the basis of keeping the biological activity of the original sequence, the key drug properties are improved in a breakthrough manner.

The present application relates to a kind of pharmaceutical composition for treating type 2 diabetes and its application.The pharmaceutical composition includes icariin, hydroxymethyl coumarin and cinnamaldehyde, by three-component synergistic effect, simultaneously act on insulin resistance, pancreatic beta cell apoptosis and systemic metabolic inflammation three type 2 diabetes core pathological links, auxiliary reduce serum lipid level, and reduce drug-related liver injury risk, good safety.Animal experiment results show that three-drug combination group can effectively reduce blood sugar (decrease about 50%), significantly improve islet structure atrophy, restore hepatocyte index arrangement, reduce glomerular hypertrophy, significantly reduce serum TG and CHOL level (P<0.05) and inflammatory factor IL-6 and TNF-alpha level (P<0.05), and avoid the hepatotoxicity risk (ALT / AST restores to close to normal level) of hydroxymethyl coumarin.The present application is composed of three kinds of natural monomers with clear structure, and has clear components and controllable quality, which provides a more optimal comprehensive treatment strategy for the treatment of type 2 diabetes and its complications.

The invention relates to the technical field of gene vectors, and discloses a multi-target multi-gene stable silencing vector and an application thereof in treating diabetes mellitus, and a multi-gene multi-target gene modification combined element is safely and efficiently integrated at a gene safety parking point of a second intron region of a CCR5 gene in a genome in a reverse fixed point manner by using a non-viral vector system; therefore, the effect of continuously silencing expression of a plurality of target genes such as MSTN, GRB10 and PTBP1 for a long time is achieved, and aging of mesenchymal stem cells cultured in vitro is remarkably inhibited. When the mesenchymal stem cells modified by the multi-target multi-gene stable silencing vector are infused, the activity is high, the chronic inflammatory microenvironment is effectively inhibited, and the senescence process is delayed; moreover, proliferation and differentiation of pancreatic beta cells are promoted, insulin secretion is enhanced, insulin resistance is effectively resisted, and diseases such as diabetes mellitus are prevented.

The present disclosure relates to a method of generating pancreatic lineage cells, e.g. islet-like cell aggregates comprising pancreatic beta cells, comprising the steps of providing a single cell suspension of a population of endocrine progenitor cells (EP), allowing the EP cells in the single cell suspension to form 3D structures, and culturing the cells under conditions allowing differentiation into pancreatic mono-hormonal beta cells. The present disclosure also relates to islet-like cell aggregates obtainable by said method and their medical use.

The invention discloses nutrition-balanced flour assisting in pancreas islet repair as well as a preparation method and application of the nutrition-balanced flour. The nutrition-balanced flour is prepared from the following raw materials in parts by mass: 40-60 parts of whole grains, 10-15 parts of beans, 5-15 parts of vital gluten, 7-10 parts of potatoes, 7-10 parts of vegetables, 5-8 parts of bacteria and algae, 5-8 parts of nut seeds, 3-5 parts of medicinal and edible food and 3-5 parts of beer yeast. The invention provides more comprehensive nutrition powder containing whole grains, beans, potatoes, nuts and the like, and further comprises common food with the effect of reducing blood sugar and medicinal and edible food which has the effect of reducing blood sugar and can prevent diabetic complications, and the nutrition flour has the following functions: balanced nutrition is provided for the body; blood sugar reduction is assisted; the islet cells are assisted to repair; and diabetic complications are prevented. The invention relates to an application of nutrition-balanced flour assisting in pancreas islet repair. The flour is used for making steamed buns, dumplings, steamed stuffed buns, wontons, noodles, cakes, biscuits or other flour products.

The present disclosure provides methods of amplifying tissue samples derived from humans for purposes of treating certain diseases. The method comprises: isolating a small amount of associated tissue by biopsy or other tissue acquisition methods; the tissue is amplified in vitro, and meanwhile, natural functions are reserved; and re-implanting the amplified tissue to alleviate human disease. One example includes ex vivo expansion of human pancreatic islet tissue and reimplantation of the expanded cells into an individual with Type 1 diabetes for treatment and long term relief or cure of disease.